As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.
A diverse range of selective FGFR4 inhibitor hit series were identified using unbiased screening approaches and by the modification of known kinase inhibitor scaffolds. In each case the origin of the selectivity was consistent with an interaction with a poorly conserved cysteine residue within the middle-hinge region of the kinase domain of FGFR4, at position 552. Targeting this region identified a non-covalent diaminopyrimidine series differentiating by size, an irreversible-covalent inhibitor in which Cys552 undergoes an SNAr reaction with a 2-chloropyridine, and a reversible-covalent inhibitor series in which Cys552 forms a hemithioacetal adduct with a 2-formyl naphthalene. In addition, the introduction of an acrylamide into a known FGFR scaffold identified a pan-FGFR inhibitor which reacted with both Cys552 and a second poorly conserved cysteine on the P-loop of FGFR4 at position 477 which is present in all four FGFR family members.
FGF19 signaling through
the FGFR4/β-klotho receptor complex
has been shown to be a key driver of growth and survival in a subset
of hepatocellular carcinomas, making selective FGFR4 inhibition an
attractive treatment opportunity. A kinome-wide sequence alignment
highlighted a poorly conserved cysteine residue within the FGFR4 ATP-binding
site at position 552, two positions beyond the gate-keeper residue.
Several strategies for targeting this cysteine to identify FGFR4 selective
inhibitor starting points are summarized which made use of both rational
and unbiased screening approaches. The optimization of a 2-formylquinoline
amide hit series is described in which the aldehyde makes a hemithioacetal
reversible-covalent interaction with cysteine 552. Key challenges
addressed during the optimization are improving the FGFR4 potency,
metabolic stability, and solubility leading ultimately to the highly
selective first-in-class clinical candidate roblitinib.
Immobilized on Merrifield polystyrene, catalyst 1 shows high activity and stability in different types of olefin metathesis. The products can be isolated in high purity by simple filtration, while the immobilized catalyst 1 can be recycled and used up to four times in the ring‐closing metathesis of 2. Mes=methane sulfonate, Ts=toluene sulfonate, Cy=cyclohexyl.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.